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This study aimed to evaluate the diagnostic accuracy of soluble triggering receptor
expressed on myeloid cells-1 (sTREM-1), midregional proatrial natriuretic peptide (MR-
proANP) and midregional proadrenomedullin (MR-proADM) to distinguish bacterial from
viral community-acquired pneumonia (CAP) and to identify severe cases in children hospi-
talized for radiologically confirmed CAP. Index test results were compared with those
derived from routine diagnostic tests, i.e., white blood cell (WBC) counts, neutrophil percent-
ages, and serum C-reactive protein (CRP) and procalcitonin (PCT) levels.
Methods
This prospective, multicenter study was carried out in the most important children’s hospitals
(n = 11) in Italy and 433 otherwise healthy children hospitalized for radiologically confirmed
CAP were enrolled. Among cases for whom etiology could be determined, CAP was
ascribed to bacteria in 235 (54.3%) children and to one or more viruses in 111 (25.6%) chil-
dren. A total of 312 (72.2%) children had severe disease.
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Results
CRP and PCT had the best performances for both bacterial and viral CAP identification. The
cut-off values with the highest combined sensitivity and specificity for the identification of
bacterial and viral infections using CRP were7.98 mg/L and7.5 mg/L, respectively.
When PCT was considered, the cut-off values with the highest combined sensitivity and
specificity were0.188 ng/mL for bacterial CAP and0.07 ng/mL for viral CAP. For the
identification of severe cases, the best results were obtained with evaluations of PCT and
MR-proANP. However, in both cases, the biomarker cut-off with the highest combined sen-
sitivity and specificity (0.093 ng/mL for PCT and33.8 pmol/L for proANP) had a relatively
good sensitivity (higher than 70%) but a limited specificity (of approximately 55%).
Conclusions
This study indicates that in children with CAP, sTREM-1, MR-proANP, and MR-proADM
blood levels have poor abilities to differentiate bacterial from viral diseases or to identify
severe cases, highlighting that PCT maintains the main role at this regard.
Introduction
Community-acquired pneumonia (CAP), with viruses and bacteria as its main causes, is one
of the leading causes of morbidity and mortality in young children worldwide [1]. Early detec-
tion of bacterial cases that have the potential for a rapid negative evolution is essential to guide
clinical management and to avoid prolonged hospitalization and the risk of death [2]. Further-
more, the differentiation of viral from bacterial CAP is necessary for the rational use of antibi-
otics and the consequent reduction in the emergence of bacterial resistance and drug-related
adverse events [3]. Unfortunately, both these goals are difficult to achieve, particularly in youn-
ger children in whom the collection of respiratory samples is difficult or impossible to obtain
[4]. Clinical signs and symptoms and radiological findings are frequently similar in cases of
viral and bacterial disease [4]. Moreover, in most cases, the results from routine laboratory
tests, such as white blood cell (WBC) count and C-reactive protein (CRP) serum level determi-
nation, tend to overlap, making the differentiation impossible [5]. This challenge also exists
when using procalcitonin (PCT) to define the etiology and severity of CAP. PCT was the latest
biomarker to enter into routine clinical practice [6].
These limitations explain why several attempts to find more effective biomarkers of CAP
bacterial etiology and disease severity have been made in recent years. Recently, it has been
suggested that soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), midregio-
nal proatrial natriuretic peptide (MR-proANP) and midregional proadrenomedullin (MR-
proADM) could improve the determination of CAP etiology and severity [7–9]. For all these
biomarkers, data collected in adults seem to indicate that their concentrations in body fluids
are increased in cases of bacterial infections, particularly in the most severe cases. However,
the available data are limited and sometimes conflicting. Moreover, to date no evaluation was
performed in children. This study aimed to evaluate the diagnostic accuracy of these new bio-
markers to distinguish bacterial from viral CAP and to identify severe CAP cases in children.
The results were compared with those derived from WBC counts, neutrophil percentages, and
serum CRP and PCT levels.
Biomarkers in Pediatric Community-Acquired Pneumonia
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Materials and Methods
Study design
This research was a prospective, multicenter study carried out in the 11 most important chil-
dren’s hospitals of Italy (Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico,
Milan; Di Cristina Hospital, Palermo; Ospedale Giovanni XXIII, Bari; Padova Hospital, Padua;
Ospedale Sant’Orsola, Bologna; Treviso Hospital, Treviso; Regina Margherita Hospital, Turin;
Santobono Hospital, Naples; IRCCS Bambino Gesu` Hospital, Rome; IRCCS Giannina Gaslini
Hospital, Genoa, Italy; and Policlinico G.B. Rossi, Verona). The protocol was approved by the
Ethics Committee of each center. Written informed consent was obtained from either the par-
ent(s) or legal guardian(s) of each study participant, and children aged >8 years provided their
written assent.
Participants
Otherwise healthy children 4 months-14 years old consecutively hospitalized for clinical signs
suggestive of CAP, such as tachypnea and abnormal breath sounds, and a radiological confir-
mation of CAP were recruited. Exclusion criteria included the presence of an underlying
chronic disease or an antibiotic treatment of any type in the 48 hours before the admission. In
each center, all chest radiographs were evaluated by an expert radiologist who classified the
findings as alveolar CAP, non-alveolar CAP or no CAP in accordance with the World Health
Organization (WHO) criteria for the standardized interpretation of pediatric chest radio-
graphs for a diagnosis of pneumonia [10]. Chest radiography characterized by presence of con-
solidation (defined as a dense or fluffy opacity that occupies a portion or whole of a lobe or of
the entire lung, that may or may not contain air-bronchograms above) or pleural effusion in
the lateral pleural space was considered indicative of alveolar CAP. Non-alveolar CAP was
diagnosed in case of linear and patchy densities (interstitial infiltrate) in a lacy pattern involv-
ing both lungs, featuring peribronchial thickening and multiple areas of atelectasis. The same
diagnosis was made when minor patchy infiltrates not of sufficient magnitude to constitute
primary consolidation and small areas of atelectasis that could not be distinguished from con-
solidation were evidenced. The CAP severity of disease was established in all the participating
hospitals using the criteria indicated for children by the British Thoracic Society (BTS) [11]. In
particular, features of severe disease in an infant were considered as follows: oxygen saturation
<92%; cyanosis; respiratory rate>70 breaths/min; significant tachycardia for the fever level;
prolonged central capillary refill time2 s; difficulty in breathing; intermittent apnea; grunt-
ing; and not feeding. Features of severe disease in an older child included the following: oxygen
saturation <92%; cyanosis; respiratory rate>50 breaths/min; significant tachycardia for the
fever level; prolonged central capillary refill time2 s; difficulty in breathing; grunting; and
signs of dehydration. Both the evaluation of the chest radiograph and the classification of
severity of each CAP episode were blinded to all the studied biological criteria, including WBC
count, and CRP and PCT serum levels. After enrollment, within minutes from hospitalization
the demographic, clinical history and clinical disease characteristics of each child were
recorded. Moreover, a blood sample was drawn at admission to the hospital and divided in
two parts: one sample was sent to the central laboratory of the hospital for the determination
of routine tests including the WBC count, the percentage of neutrophils, and CRP level; the
second sample was used for the determination of PCT, sTREM-1, MR-proANP, and MR-
proADM levels as well as for pneumococcal and Mycoplasma pneumoniae detection. Finally, a
nasopharyngeal swab was obtained from all the enrolled children using a pernasal nylon
flocked swab and was stored in a tube of universal transport medium (Kit Cat. No. 360c,
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Copan Italia, Brescia, Italy) for respiratory virus, Streptococcus pneumoniae, and Mycoplasma
pneumoniae detection. The serum of the blood samples that had to be used for new biomark-
ers’ serum level determination and nasopharyngeal samples were conserved in freezer at -80˚C
in each center and later sent to the laboratory of the Pediatric High Intensity Care Unit of the
University of Milan for centralized processing.
Test methods
Biomarker determination. WBC counts, neutrophil percentages and serum CRP levels
were determined by the central laboratory of the hospital using routine methods. sTREM-1
concentrations were measured using an ELISA according to the manufacturer’s instructions
(IQ Products, Groningen, the Netherlands) with a detection level of<7 pg/mL. An automated
immunofluorescent assay was used for the determination of the levels of MR-proADM, MR-
proANP and PCT according to the manufacturer’s instructions (BRAHMS, Germany). The
functional assay sensitivity was previously assessed as being less than 0.25 nmol/L for MR-
proADM, 10 pmol/L for MR-proANP, and 0.06 ng/mL for PCT. The detection limit that was
calculated using the imprecision profile was previously assessed as being 0.02 ng/mL with a
probability of 95% for PCT, 0.05 nmol/L for MR-proADM, and 2.1 pmol/L for MR-proANP.
sTREM-1, MR-proADM, MR-proANP and PCT were chosen due to the sensitivity and speci-
ficity showed in adults with CAP for differentiating viral and bacterial CAP or severe and non-
severe CAP [7–9]. Clinical and radiographic information, new biomarkers’ serum level deter-
minations and results on nasopharyngeal samples were not available for the central laboratory
of the hospital where routine methods were performed. Two different persons in the labora-
tory of the Pediatric High Intensity Care Unit of the University of Milan performed the deter-
mination of the new biomarkers and the viral and bacterial analyses on nasopharyngeal
samples without exchanging information and in absence of any clinical and radiographic
information.
Respiratory virus detection. Viral RNA or DNA was extracted from the respiratory
secretions within 24 hours of collection using a Nuclisens EasyMAG automated extraction sys-
tem (bioMe´rieux, Craponne, France) and was then tested using the Luminex x TAG respira-
tory virus panel fast assay (Luminex Molecular Diagnostics Inc., Toronto, Canada) to detect
influenza A virus (subtype H1 or H3), influenza B virus, respiratory syncytial virus (RSV)-A
and -B, parainfluenzavirus-1, -2, -3 and -4, adenovirus, human metapneumovirus (hMPV),
coronaviruses 229E, NL63, OC43 and HKU1, enterovirus/rhinovirus (RV) and human boca-
virus in accordance with the manufacturer’s instructions. The enterovirus/RV-positive sam-
ples were retested using a real-time polymerase chain reaction (PCR) assay using the iAg-
Path-ID one step RT-PCR kit (Applied Biosystems, Foster City, CA) and the primers and
probe sequences reported by Lu et al. to identify RV cases [12].
Streptococcus pneumoniae and Mycoplasma pneumoniae detection. To identify pneu-
mococcal cases, nucleic acid extracts from blood and swab samples were tested for the autoly-
sin-A (LytA) and wzg (cpsA) genes of S. pneumoniae using real-time PCR as previously
described [13]. Each sample was tested in triplicate and was considered positive if at least 2 of
the 3 tests were positive. To maximize sensitivity, no internal amplification control was used in
the reaction, but there was an external control.
M. pneumoniae was looked for in blood and nasopharyngeal swabs with validated, nested
PCR, as described previously [14].
Identification of probable bacterial and viral infection. Chest radiographs with alveolar
or non-alveolar findings were initially classified as of possible bacterial or of possible viral ori-
gin, respectively, according to the WHO indication [10]. Then, radiological findings were
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coupled with results of the real-time PCR tests on blood samples and nasopharyngeal swabs.
Evidence of S. pneumoniae or M. pneumoniae in these samples further supported bacterial eti-
ology. Notably, S. pneumoniae can be detected in the nasopharyngeal secretions of children
with viral CAP [15], but its presence in absence of viral detection in children with alveolar
CAP is suggestive of probable pneumococcal CAP [16–18]. Moreover, even if it has been
recently reported that M. pneumoniae is frequently carried in otherwise healthy children [19],
it seems reasonable to think than when this pathogen is detected in children with CAP in
absence of S. pneumoniae or respiratory viruses, it is the real cause of the lower respiratory
infection independent of the radiological characteristics [20]. Finally, the presence of one or
more respiratory viruses in the nasopharynx is commonly considered the etiologic agent of
CAP because carriage of viruses in healthy subjects is uncommon [21]. In practical terms,
CAP was considered to have a probable bacterial (PB) origin in the presence of 1) the detection
of S. pneumoniae and M. pneumoniae in the blood with a chest radiograph indicative of any
type of CAP; 2) a nasopharyngeal swab positive for S. pneumoniae associated with chest radio-
graph suggesting alveolar CAP; and 3) a nasopharyngeal swab positive for M. pneumoniae
associated with chest radiograph suggesting any type of CAP. Probable viral (PV) CAP was
diagnosed in the presence of a nasopharyngeal swab that was positive for one or more respira-
tory viruses associated with a chest radiograph leading to the diagnosis of non-alveolar CAP.
Cases that could not be included in these groups were considered undetermined. Clinical
information and blood test results were not available to the person that made this final classifi-
cation of bacterial versus viral CAP:
Analysis
A total sample size of 430 patients (assuming that about 60% of them have bacterial infection)
achieves 80% power, with alpha = 0.05, to detect a change in sensitivity from 0.70 to 0.78 (and
83% power to detect a change in specificity from 0.7 to 0.8), using a two-sided binomial tests.
Sample size was computed using PASS software v.11 (NCSS, LCC, Kaysville, Utah, USA).
All PB cases and all PV cases were evaluated together. Continuous variables are presented
as the mean ± standard deviation (SD), and categorical variables are presented as numbers and
percentages. Comparisons between groups (i.e., PB vs PV and severe vs non-severe CAP) were
performed using the χ2 or Fisher’s exact test, as appropriate (for categorical variables), or a
two-sided Student’s t-test after confirming that the data were normally distributed (based on
the Shapiro-Wilk statistic) or a two-sided Wilcoxon’s rank-sum test otherwise (for continuous
variables). Diagnostic performances of the biomarkers were evaluated with Receiver Operating
Characteristic (ROC) curves and the area under ROC curve (AUC). The best cut-off values for
different biomarkers were obtained based on the highest sensitivity and specificity through the
roctab function in STATA. In case of indeterminate results for CRP and new biomarkers, the
lowest limit of detection of the various methods was considered. Missing data were reported in
the Tables and the missing information was not included in the statistical analyses. All analyses
were conducted using SAS version 9.2 (Cary, NC, USA) and STATA version 11.0 (StataCorp
LP, College Station, Tex) statistical packages.
Results
Participants
A total of 433 children (males, 56.0%; mean age 4.2 ± 3.5 years) with radiologically confirmed
CAP were enrolled. Their demographic, clinical and laboratory characteristics are reported in
Table 1. Results on respiratory viruses, S. pneumoniae, and M. pneumoniae were available for
all the patients. CAP was ascribed to bacteria in 235 (54.3%) children and to one or more
Biomarkers in Pediatric Community-Acquired Pneumonia
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viruses in 111 (25.6%) children. In 87 cases (20.1%), the etiology of the disease was undeter-
mined. Bacteremia was detected in 28 cases (6.5%): S. pneumoniae in 27 cases and M. pneumo-
niae one case. Globally, S. pneumoniae was considered the probable etiologic agent in 195
(83.0%) PB cases, and M. pneumoniae was considered the probable etiologic agent in 40 (17%)
cases. Among PV CAP, RSV and RV were the most common and were detected as single path-
ogens in 52 (46.8%) and 12 (10.8%) children, respectively. In the remaining cases (47, 42.4%),
co-infections between these viruses and other viral agents were found. Moreover, 312 (72.2%)
children had severe disease. Among them, 178 (57.0%), 78 (25.0%), and 56 (18.0%) had a PB, a
PV or an undetermined infection, respectively.
Diagnostic performance of the studied biomarkers to predict CAP
etiology
At admission, the percentage of neutrophils was significantly higher in children with PB than
in those with PV CAP (63.6% ± 20.7 vs 56.6 ± 19.7; p<0.05). Similar results were observed for
both CRP and PCT (CRP, 21.3 ± 48.1 mg/L in PB and 8.0 ± 30.4 mg/L in PV cases, p<0.05;
PCT, 6.1 ± 17.0 ng/mL in PB and 1.1 ± 3.4 in PV CAP, p<0.05). Moreover, the levels of MR-
Table 1. Demographic, clinical, laboratory and radiographic variables in 433 children, according to their infection status*.
Variable All subjects Probable bacterial Probableviral Undetermined
n = 433 n = 235 n = 111 n = 87
Demographics and clinical presentation
Males (%) 242 (56.0) 140 (59.8) § 53 (47.7) § 49 (56.3)
Mean age ± SD (years) 4.2 ± 3.5 4.9 ± 3.6 §& 2.8 ± 2.4 §c¸ 3.9 ± 3.5 &c¸
Caucasians (%) 359 (85.7) 198 (87.2) 88 (83.0) 73 (84.9)
At least one parent smoked (%) 153 (36.9) 80 (35.6) 43 (40.6) 30 (35.7)
Presence of fever” (%) 287 (66.7) 173 (73.9) §& 63 (57.3) § 51 (59.3) &
O2 therapy (%) 139 (33.3) 65 (28.4) § 46 (44.2) § 28 (33.3)
Clinical findings (%)
Rhonchi 83 (19.3) 31 (13.2) § 36 (32.4) §c¸ 16 (18.6) c¸
Rales 351 (81.4) 186 (79.5) § 98 (88.3) § 67 (77.9)
Wheezing 104 (24.1) 45 (19.2) § 34 (30.6) § 25 (29.1)
Any of the above 365 (84.7) 192 (82.0) § 103 (92.8) §c¸ 70 (81.4) c¸
Severe disease 312 (72.2) 178 (75.7) 78 (70.3) 56 (65.1)
Laboratory data Mean ± SD (n) Mean ± SD (n) Mean ± SD (n) Mean ± SD (n)
WBC (cells/μL) 14213 ±8570 (428) 14776 ± 9104(232) 12523 ± 6436 (111) 14886 ± 9279 (85)
CRP, mg/L 16.7 ± 42.6 (426) 21.3 ± 48.1(232)§& 8.0 ± 30.4 (110)§c¸ 15.4 ± 38.7 (84)&c¸
Neutrophils, % 61.2 ± 20.7 (413) 63.6 ± 20.7 (222)§ 56.6 ± 19.7 (109)§ 60.7 ± 21.2 (82)
PCT, ng/mL 4.1 ± 13.9 (265) 6.1 ± 17.0 (132) §& 1.1 ± 3.4 (78)§ 3.5 ± 14.4 (55)&
sTREM-1, pg/mL 95.7 ± 186.8 (405) 101.2 ± 193.1 (214) 82.5 ± 190.4 (108) 98.8 ± 165.7 (83)
MR-proANP, pmol/L a 55.0 ± 48.6 (408) 53.0 ± 44.3 (222) 57.9 ± 56.2 (106) 56.8 ± 49.5 (80)
MR-proADM, nmol/L a 0.44 ± 0.71 (410) 0.50 ± 0.94 (223) & 0.37 ± 0.16 (106) 0.35 ± 0.17 (81)&
CRP, C-reactive protein; PCT, procalcitonin; SD, standard deviation; sTREM, soluble triggering receptor expressed on myeloid cells-1; MR-proANP,
midregional proatrial natriuretic peptide; MR-proADM, midregional proadenomedullin; WBC, white blood cell count. Results on respiratory viruses,
Streptococcus pneumoniae, and Mycoplasma pneumoniae were available for all the patients.
*The sums do not add up to the total because of missing values.
§p<0.05 for comparison between probable bacterial and probable viral infection groups.
&p<0.05 for comparison between probable bacterial and undetermined infection groups.
c¸p<0.05 for comparison between probable viral and undetermined infection groups.
doi:10.1371/journal.pone.0163262.t001
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proADM found in PB CAP cases were significantly higher than those in undetermined CAP
cases (0.50 ± 0.94 vs 0.35 vs ± 0.17, p< 0.05).
For the evaluation of the diagnostic performance of the studied biomarkers, only children
with defined PB or PV CAP were considered. Diagnostic performance of studied biomarkers
at enrollment to predict bacterial and viral infections is reported in Table 2. All of them had
low AUC values. However, CRP and PCT had the best performances for both PB (AUC of
0.66, 95% CI: 0.61–0.71, and 0.69, 95% CI: 0.63–0.75, respectively) and PV (AUC of 0.68, 95%
CI: 0.62–0.63, and 0.67, 95% CI: 0.60–0.64, respectively) CAP identification. Cut-off values
with the highest sensitivity and specificity combination for the identification of PB and PV
infections using CRP were7.98 mg/L and7.5 mg/L, respectively. When PCT was consid-
ered, the cut-off values with the highest combined sensitivity and specificity were0.188 ng/
mL for PB CAP and0.07 ng/mL for PV CAP. sTREM-1, MR-proANP, and MR-proADM
had predictive values for both PB and PV infections that were lower than that evidenced for
CRP and PCT but were not higher than that from the WBC count and neutrophil percentage,
as evidenced by the AUC value that was lower than 0.60.
Diagnostic performance of studied biomarkers to predict severity of CAP
Table 3 shows the biomarker levels at enrollment according to the severity of the disease. All
the studied parameters, with the exception of MR-proADM, were significantly higher in severe
CAP compared with non-severe CAP (p<0.01 for MR-proANP, WBC count, neutrophil per-
centage and PCT; p<0.05 for sTREM-1 and CRP).
Even for the identification of severe cases, the predictive value of all the studied biomarkers
was poor (Table 4). The best results were obtained when PCT (AUC = 0.65, 95% CI: 0.57–
0.63) and MR-proANP (AUC = 0.65, 95% CI: 0.59–0.71) were evaluated. However, in both
Table 2. Diagnostic performance of soluble triggering receptor expressed on myeloid cells-1 (sTREM), midregional proatrial natriuretic peptide
(proANP) and midregional proadenomedullin (proADM) biomarkers, as compared to white blood cell (WBC) count, neutrophils percentage, C
reactive protein (CRP) and procalcitonin (PCT) at enrolment to predict bacterial and viral infections, according to biomarker cut-off with highest
sensitivity and specificity.
Variable n Biomarker cut-off value Sensitivity Specificity PPV NPV AUC (95% CI)
Probable bacterial infection (n = 235)
sTREM-1, pg/mL 405 69.56 31.8% 73.7% 58.1% 48.4% 0.50 (0.45–0.56)
MR-proANP, pmol/L* 408 59.1 76.1% 33.1% 58.3% 53.1% 0.52 (0.46–0.57)
MR-proADM, nmol/L 410 0.32 78.0% 35.7% 59.8% 57.0% 0.58 (0.52–0.63)
WBC count, cells/μL 428 12870 46.1% 61.3% 59.1% 48.3% 0.52 (0.47–0.58)
CRP mg/L 426 7.98 50.9% 80.4% 76.1% 57.1% 0.66 (0.61–0.71)
Neutrophils, % 413 61.0 63.5% 53.8% 62.1% 55.2% 0.58 (0.53–0.64)
PCT, ng/mL 265 0.188 67.4% 65.1% 66.4% 66.1% 0.69 (0.63–0.75)
Probable viral infection (n = 111)
sTREM-1, pg/mL* 405 59.28 72.2% 36.4% 29.4% 78.1% 0.52 (0.46–0.58)
MR-proANP, pmol/L* 408 35.5 46.2% 61.5% 29.9% 76.3% 0.51 (0.44–0.57)
MR-proADM, nmol/L* 410 0.31 35.8% 73.4% 32.2% 76.5% 0.53 (0.46–0.59)
WBC count, cells/μL* 428 15740 78.4% 33.1% 29.3% 81.2% 0.56 (0.50–0.62)
CRP, mg/L* 426 7.5 88.2% 46.3% 36.6% 91.8% 0.68 (0.62–0.73)
Neutrophils, %* 413 60.8 56.9% 60.1% 34.1% 79.4% 0.60 (0.54–0.66)
PCT, ng/mL* 265 0.07 48.7% 81.1% 52.0% 78.9% 0.67 (0.60–0.74)
AUC, area under the curve; 95% CI, 95% confidence interval; NPV, negative predictive value; PPV, positive predictive value.
*Inverse relationship between biomarker and probable bacterial/viral infection.
doi:10.1371/journal.pone.0163262.t002
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cases, the biomarker cut-off with the highest combined sensitivity and specificity (0.093 ng/
mL for PCT and33.8 pmol/L for proANP) had relatively good sensitivity (higher than 70%)
but limited specificity (of approximately 55%). Other biomarkers were even less effective (all
AUC< 0.60).
Discussion
This study is the first to evaluate the utility of serum sTREM-1, MR-proANP, and MR-
proADM concentrations in predicting the etiology and severity of pediatric CAP in compari-
son to routine biomarkers. In this study, to overcome the clinical, radiological and laboratory
problems that limit the definition of etiology and severity of CAP in children, the identification
of bacterial and viral CAP was based on the criteria usually accepted by the international litera-
ture [16–18]. A combined evaluation of radiological findings and detection in the blood and in
nasopharyngeal samples of the most important respiratory viral and bacterial agents of CAP in
children, was performed. Moreover, to establish severity, the criteria suggested by BTS were
used. Despite a certain number of CAP cases, probably those due to mixed infection, remained
Table 3. Biomarkers at enrolment according to the severity of disease&.
Severe disease (n = 312) Non-severe disease (n = 120)
Biomarker n Mean ± SD n Mean ± SD
sTREM-1, pg/mL 290 100.3 ± 198.3 § 114 84.8 ± 154.8 §
MR-proANP, pmol/L 292 57.8 ± 46.4 * 115 45.4 ± 44.8 *
MR-proADM, nmol/L 294 0.42 ± 0.38 115 0.48 ± 1.19
WBC count, cells/μL 309 14763 ± 8552 * 119 12786 ± 8489 *
CRP, mg/L 307 17.9 ± 45.6 § 119 13.7 ± 33.7 §
Neutrophils, % 296 62.9 ± 20.4 * 117 56.7 ± 20.7 *
PCT, ng/mL 194 4.6 ± 15.3 * 71 2.6 ± 9.1 *
CRP, C-reactive protein; PCT, procalcitonin; SD, standard deviation; sTREM, soluble triggering receptor expressed on myeloid cells-1; MR-proANP,
midregional proatrial natriuretic peptide; MR-proADM, midregional proadenomedullin; SD, standard deviation; WBC, white blood cell count.
& One subject could not be categorized as severe or non-severe disease due to missing data.
§ p<0.05 for comparison between severe and non-severe disease groups.
* p<0.01 for comparison between severe and non-severe disease groups.
doi:10.1371/journal.pone.0163262.t003
Table 4. Diagnostic performance of soluble triggering receptor expressed on myeloid cells-1 (sTREM), midregional proatrial natriuretic peptide
(proANP) and midregional proadenomedullin (proADM) biomarkers, as compared to white blood cell (WBC) count, neutrophils percentage, C
reactive protein (CRP) and procalcitonin (PCT) at enrolment to predict severity of disease, according to biomarker cutoff with highest sensitivity
and specificity.
Variable n Biomarker cut-off value Sensitivity Specificity PPV NPV AUC (95% CI)
Severe disease (n = 312)
sTREM-1, pg/mL 404 16.32 77.2% 38.6% 76.2% 40.0% 0.57 (0.51–0.64)
MR-proANP, pmol/L 407 33.8 70.9% 56.5% 80.5% 43.3% 0.65 (0.59–0.71)
MR-proADM, nmol/L 409 0.39 51.4% 66.1% 79.5% 34.7% 0.55 (0.49–0.61)
WBC count, cells/μL 428 13240 44.7% 71.4% 80.2% 33.2% 0.59 (0.53–0.65)
CRP, mg/L 426 1.04 77.2% 41.2% 77.2% 41.2% 0.58 (0.52–0.64)
Neutrophils % 413 55.4 69.9% 50.4% 78.1% 39.9% 0.59 (0.53–0.65)
PCT, ng/mL 265 0.093 76.8% 57.7% 83.2% 47.7% 0.65 (0.57–0.73)
AUC, area under the curve; 95% CI, 95% confidence interval; NPV, negative predictive value; PPV, positive predictive value.
doi:10.1371/journal.pone.0163262.t004
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undetermined, this method has probably lead to the identification of those CAPs which are
more likely due only to bacteria or only to viruses. Interestingly, as reported in several recent
studies and probably thanks to the new molecular diagnostic methods that permit us to enlarge
in comparison with the past possibilities for viral identification [4], the prevalence of PB and
PV among children with severe CAP was similar. A global evaluation of the results of this
study seemed to indicate that in children with CAP, sTREM-1, MR-proANP, and MR-
proADM blood levels are unable to differentiate bacterial from viral diseases or to identify
severe cases. At admission, the mean values of all these biomarkers were similar in PB and PV
cases. When attempts to evaluate the sensitivity and specificity of each of these biomarkers in
defining the etiology and severity of the studied CAP cases were made, either the sensitivity or
the specificity was found to be very low, leading to a modest predictive value. This result was
confirmed by the values of the AUC, which were always below 0.70 for a single biomarker for
both the definition of the etiology and the assessment of severity, a value that suggests poor
accuracy of the studied tests. Moreover, for the definition of the etiology of pediatric CAP, the
predictive ability of these biomarkers seemed to be lower than that of CRP and PCT, whereas
for the identification of severe cases the best results were obtained with evaluations of PCT
and MR-proANP.
The diagnostic relevance of sTREM-1 in bacterial diseases, including CAP, has been studied
in experimental animal studies and in adult humans with conflicting results. Some studies
have reported that in cases of sepsis or CAP, sTREM-1 is a superior indicator of bacterial dis-
ease compared with CRP and PCT [22, 23]. Moreover, it was demonstrated that sTREM-1 lev-
els were significantly higher in neonates with sepsis than in healthy controls [24]. Finally, in
children with bronchiectasis, sTREM-1 sputum levels correlated with markers of neutrophilic
inflammation but not necessarily with CRP concentrations, suggesting that sTREM-1 may be
more sensitive in detecting pulmonary neutrophilic inflammation than CRP [25]. However,
other studies have reported results similar to those found by our study. In adults with ventila-
tor-associated pneumonia, sTREM1 was a poor predictor of VAP among critically ill subjects
undergoing direct bronchoscopy [26, 27]. Different patient and sample characteristics used to
measure sTREM-1 concentrations might explain the different results. In most of the cases
showing a role for sTREM-1 in the diagnosis of bacterial infection, the data were collected in
patients with a chronic underlying disease who were hospitalized in intensive care unit,
whereas in this study, only otherwise healthy children with an acute CAP episode were
enrolled. Moreover, the different criteria used to classify the etiology and severity of CAP
could explain the differences among the results presented in the literature.
Changes in MR-proANP have been associated with acute and chronic heart failure [28],
although the prognostic value of this biomarker in CAP seems to be maintained independent
of chronic heart failure [29]. Moreover, in diseases associated with bacteremia, this biomarker
is increased [30]. Because CAP with bacteremia is generally the most severe, it was concluded
that this biomarker could simultaneously detect bacterial CAP and identify the most severe
cases. Alan et al. reported that the addition of blood biomarkers, including MR-proANP, to
clinical scores significantly improved the prognostic capabilities of the pneumonia severity
index [31]. Kruger et al. reported that MR-proANP was a good predictor of mortality risk in
patients with CAP [29]. However, the poor ability by MR-proANP to predict bacteremia in
patients with CAP was evidenced by Guinard-Barbier et al. [32]. Additionally, in this case, dif-
ferences in the characteristics of the studied patients might explain the results. None of the
children in our study had chronic heart failure, and the number of bacteremia cases was very
small. It is possible that the blood levels of this biomarker significantly increased and had a
true prognostic value only in very severe bacteremic cases of CAP. Moreover, the criteria used
in this study to measure severity were different from those used in the studies in which adults
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were enrolled. In those studies, severity was measured considering the final outcome of the dis-
ease, whereas in this study, consistent with pediatric guidelines, severity was considered only
at admission.
Similar conclusions can be drawn for the MR-proADM evaluation. Additionally, this
marker has been tested mainly as a marker of severity, although there are data indicating that
it can be of value in the diagnosis and prognosis of sepsis and bacterial CAP [9]. Once again, it
seems highly likely that modifications of this biomarker occur only in very severe bacterial dis-
eases that are relatively uncommon iamong children with CAP.
The problems that pediatricians have in differentiating bacterial from viral CAP and in
assessing the severity of the disease are highlighted by the poor predictive value evidenced in
this study for WBC count, neutrophil percentage, and CRP and PCT levels. CRP and PCT
were slightly better than WBC count and neutrophil percentage. However, the importance of
CRP and PCT in the definition of the etiology and the severity of pediatric CAP has been
largely studied and discussed with conflicting results. CRP as a type of acute-phase reaction
protein is closely related with inflammatory reaction and tissue injuries and can be influenced
by factors other than bacterial components. For many years, it has been shown that only
extremely high CRP serum levels are associated with bacterial disease and a negative prognosis,
whereas in many cases, such values do not permit an estimate of the real etiology of the disease
[32–34]. Cohen et al. showed that PCT and not CRP was the only independent predictor of
apyrexia in children hospitalized for CAP [35]. However, recently, it has been reported that
CRP can predict outcomes of pediatric CAP cases because CRP levels are significantly associ-
ated with both fever duration and hospital length of stay [36]. For every 1 mg/dL increase in
CRP, the length of stay increased by 1 hour. Moreover, it was shown that extremely elevated
CRP levels are associated with unfavorable outcomes, including death, in pediatric patients,
highlighting the importance of very high levels, uncommonly assessed in daily practice [37].
Similarly, the results reported for PCT are inconsistent. Nascimento-Carvalho et al. showed
that in 95 children, PCT had a negative predictive value for differentiating bacteremic infec-
tions from viral infections, atypical bacterial infections, and nonbacteremic typical bacterial
infections [38]. More recently, Galetto-Lacour et al. reported a positive role of PCT in differen-
tiating bacterial from viral CP, particularly when the disease was due to S. pneumoniae [39].
Additionally, we previously used a PCT cut-off value to identify PV CAP and to guide antibi-
otic therapy [40]. Conflicting results were reported in other studies. Korpi et al. reported that
PCR had a sensitivity in the identification of bacterial CAP of only 55% [41], whereas later,
these authors found that high values of PCT5 ng/mL were associated with a high predictivity
of bacterial CAP [42]. However, it seems evident that only very high serum concentrations of
PCT are predictive of true bacterial CAP. Regarding PCT and disease severity, a study by Don
et al. found that higher mean values were present in children who needed hospitalization; addi-
tionally, in this case, a non-marginal number of cases could not be classified because of similar
results among children with mild and severe disease [43].
Limitations of our study include the missing data for laboratory biomarkers in some
patients, potential classification bias in the etiologic diagnosis, and the fact that patients with
undetermined infection were excluded from the analysis. However, our evaluation has been
done in a large study population with an appropriate calculation of sample size even excluding
patients with undetermined infection. In addition, viral and bacterial results in nasopharyngeal
aspirates and blood were available for all the study patients. Moreover, a sophisticated statisti-
cal analyses has been performed, although further research on the role of the studied biomark-
ers in CAP and other infectious diseases is recommended.
In conclusion, most of the problems related to the evaluation of the PB or PV origin of a
pediatric CAP case together with the prevision of its outcome remain unsolved. No advantages
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are given by the use of sTREM-1, MR-proANP, and MR-proADM, whereas PCT maintains its
role. More studies are needed to assure a proper approach to CAP therapy in children and to
avoid the risk of useless antibiotic therapy.
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